Tazemetostat for epithelioid sarcoma NDA submitted to FDA on May 30.
Phase 2 data looks good.
Label expansion could be ahead as well.
Epizyme (EPZM) specializes in an epigenetic therapy approach to human diseases, including cancers. This is a new field and potentially a revolutionary one. Proving a drug from the epigenetics platform can work well